Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma.
Saved in:
| Title: | Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma. |
|---|---|
| Authors: | Yao Y; Department of Oncology, Mayo Clinic, Rochester, MN, United States., Yan Y; Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL, United States., Suman VJ; Department of Health Sciences, Division of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States., Dietz AB; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States., Erskine CL; Department of Immunology, Mayo Clinic, Rochester, MN, United States., Dimou A; Department of Oncology, Mayo Clinic, Rochester, MN, United States., Markovic SN; Department of Oncology, Mayo Clinic, Rochester, MN, United States.; Department of Immunology, Mayo Clinic, Rochester, MN, United States., McWilliams RR; Department of Oncology, Mayo Clinic, Rochester, MN, United States., Montane HN; Department of Oncology, Mayo Clinic, Rochester, MN, United States., Block MS; Department of Oncology, Mayo Clinic, Rochester, MN, United States.; Department of Immunology, Mayo Clinic, Rochester, MN, United States. |
| Source: | Frontiers in immunology [Front Immunol] 2025 Feb 04; Vol. 16, pp. 1491448. Date of Electronic Publication: 2025 Feb 04 (Print Publication: 2025). |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2025.1491448 |
